Clinical Case 3: A 56-Year-Old Man With Multiple Myeloma


Expert hematologist-oncologists review the case of a 56-year-old man with multiple myeloma who received CAR T-cell therapy and share their approaches to treatment.

Nina Shah, MD: We’ll now move on to module 3, “CAR T-cell Therapies in Multiple Myeloma,” and talk about recent advances. Before we do that, we’ll start off with another case. This is a 56-year-old man who was diagnosed with IgG kappa myeloma in January of 2016 and at the time presented with R-ISS [Revised International Staging System] and ISS [International Staging System] stage II with a free kappa of 129 mg/L and an LDH [lactate dehydrogenase] of 156 U/L. The cytogenetics were normal. There were lytic lesions detected on PET [positron emission tomography] and his past medical history is fairly unremarkable.

He received VRd [bortezomib (Velcade), lenalidomide (Revlimid), dexamethasone] induction therapy followed by high-dose chemotherapy and autologous stem cell transplant, and then went on to lenalidomide maintenance therapy. Two years later, he had a serologic progression, and upon further staging had evidence of new lytic lesions. He then received daratumumab [Darzalex]/carfilzomib [Kyprolis]/dexamethasone, but developed hypertension during follow-up, which was fairly well managed with medication. He was able to be on daratumumab/Kd [carfilzomib, dexamethasone] for 17 months, and then ultimately had progression. After that, he was started on pomalidomide [Pomalyst]/cyclophosphamide/dexamethasone. He received 3 cycles and had a PR [partial response], but very quickly progressed on treatment.

Given that he had these 3 lines, he was enrolled in the CARTITUDE-1 trial and received a single infusion of cilta-cel [ciltacabtagene autoleucel] and achieved a CR [complete response] by about 3 months following treatment initiation. He tolerated the treatment well and is doing well, so this is 1 of the success stories of CAR [chimeric antigen receptor] T-cell therapy. Let’s do a little round robin again. Josh, do you agree with this treatment approach?

Joshua Richter, MD: Of course, I’m going to say yes. At the recent ASH [American Society of Hematology Annual Meeting], your partner Thomas Martin, MD, from University of California, San Francisco presented some absolutely amazing data from CARTITUDE-1. What’s amazing to me isn’t just the depths of responses, but the durability, especially in heavily relapsed patients. We still need to work to figure out who needs a bispecific and who needs CAR T. But some type of T cell redirection needs to be part of an approach to a patient like this, and this is a great way to go. I couldn’t agree more.

Nina Shah, MD: Great. Ola, what do you think? Would you have done a similar thing?

Ola Landgren, MD, PhD: It’s an excellent idea. I agree with Josh. It’s the right thing to do in 2021 and beyond.

Nina Shah, MD: Great. Sagar?

Sagar Lonial, MD, FACP: Yes. What’s really interesting is that even though they didn’t have high-risk genetics, they clearly had high-risk myeloma, with relapse within 2 years on pretty good therapy. This is a nice result. The real question is, how long is it going to last? We don’t know the answer to that.

Nina Shah, MD: Right. Katja, what do you think about this approach?

Katja Weisel, MD: I agree. It would even be in label for ide-cel [idecabtagene vicleucel] here, because with 3 prior lines that would be a decent approach for even the second CAR T-cell construct. This is absolutely the way to go, especially in such a clinically high-risk patient. I would have done the same, with that potential and the great data we recently saw with cilta-cel [ciltacabtagene autoleucel].

Nina Shah, MD: Yes, and you make a really good point that this patient had 3 lines of therapy and there are different approval structures. In the United States, the patient would have had to have 4 lines of therapy for standard of care. Although cilta-cel [ciltacabtagene autoleucel] isn’t approved at the time of this filming, we think that it might be similar to ide-cel [idecabtagene vicleucel]. There are some things you’ve got to work out, but I agree that this is a perfect approach for this particular patient.

Transcript Edited for Clarity

Related Videos
C. Ola Landgren, MD, PhD
Muhamed Baljevic, MD, FACP
Muhamed Baljevic, MD
Carrie L. Kitko, MD
Lori A. Leslie, MD
Sundar Jagannath, MBBS
S. Vincent Rajkumar, MD
Muhamed Baljevic, MD
Sundar Jagannath, MBBS
Sundar Jagannath, MBBS